11/25/20 8:42 AMNasdaq : EIGREiger BioPharmaceuticals Announces FDA Approval of Zokinvy(TM) (lonafarnib): The First Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid LaminopathiesEiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Zokinvy (TM)RHEA-AIpositive
11/23/20 8:00 AMNasdaq : EIGREiger BioPharmaceuticals Sells Priority Review Voucher for $95 MillionEiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that it has entered into a definitive agreement to sell its Priority ReviewRHEA-AIvery positive
11/20/20 5:53 PMNasdaq : EIGREiger BioPharmaceuticals Announces FDA Approval of Zokinvy(TM) (lonafarnib): The First Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid LaminopathiesEiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Zokinvy TMRHEA-AIpositive
11/17/20 8:00 AMNasdaq : EIGREiger Announces Positive Peginterferon Lambda - Lonafarnib Combination End of Study Results from Phase 2 LIFT HDV Study in Late-Breaker Session at The Liver Meeting Digital Experience(TM) 2020Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of first-in-class therapies for serious rare and ultra-rare diseases, today announced a late-breaker oral presentation of Phase 2 LIFT ( L ambda I nter FRHEA-AIneutral
11/16/20 4:05 PMNasdaq : EIGREiger Announces Case Studies Demonstrating Regression of Liver Fibrosis Following 48 Weeks of Therapy with Peginterferon Lambda in Patients with Chronic Hepatitis Delta Virus (HDV) Infection Presented at The Liver Meeting Digital Experience(TM) 2020Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of first-in-class therapies for serious rare and ultra-rare diseases, today announced a poster presentation of two case studies from the completed Phase 2RHEA-AIneutral
11/11/20 8:00 AMNasdaq : EIGREiger Bio to Participate in November 2020 Investor ConferencesEiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will participate in two investor conferences inRHEA-AIneutral
11/05/20 4:05 PMNasdaq : EIGREiger BioPharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business UpdateEiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported financial results for third quarter 2020 and provided a businessRHEA-AIneutral
11/02/20 4:30 PMNasdaq : EIGREiger Announces Abstracts Highlighting Peginterferon Lambda and Lonafarnib in Chronic Hepatitis Delta Virus (HDV) Infection Accepted for Presentation at The Liver Meeting Digital Experience(TM) 2020Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted, first-in-class therapies for serious rare and ultra-rare diseases, today announced that data from its Hepatitis Delta Virus (HDV) programs areRHEA-AIneutral
10/15/20 8:00 AMNasdaq : EIGREiger BioPharmaceuticals Announces Positive Results of Investigator Sponsored Randomized Controlled Trial at University of Toronto with Peginterferon Lambda in Outpatients with Mild to Moderate COVID-19Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced results of the ILIAD Study ( I nterferon L ambda for I mmediate A ntiviralRHEA-AIneutral
09/28/20 8:00 AMNasdaq : EIGREiger Announces Results of Investigator Sponsored Study in Outpatients with Mild and Uncomplicated COVID-19Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced results of an investigator sponsored study of Peginterferon Lambda-1aRHEA-AIneutral
